Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 3, 2017. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a corporate governance notification regarding share capital.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details the static share capital position as of March 31, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, risk factors, or contingencies. It is a statutory disclosure of share counts intended to assist shareholders in calculating notification thresholds under Financial Conduct Authority rules.
Important Facts for Investors
- Issued Share Capital: As of March 31, 2017, the Company had 5,370,505,886 ordinary shares of 25 pence each.
- Treasury Shares: 453,205,950 ordinary shares were held in Treasury.
- Total Voting Rights: The total number of voting rights is 4,917,299,936.
- Usage: This voting rights figure serves as the denominator for shareholders determining if they must notify the market of their interest under Disclosure and Transparency Rules.